Curevac announces start of combined phase 1/2 study in avian influenza (h5n1); development in collaboration with gsk

Phase 1 part of combined phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (h5n1) virus, considered to be potential future pandemic threat study will assess monovalent vaccine candidate, encoding an influenza a h5-antigen using proprietary second-generation mrna backbone avian influenza is latest program progressing to clinical trials under broad infectious disease collaboration agreement with gsk tÜbingen, germany and boston, ma / accesswire / april 24, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the start of the phase 1 part of a combined phase 1/2 study of an investigational influenza a (h5n1) pre-pandemic vaccine candidate developed in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking